Lynnetta M. Watts

miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting

Christine Esau, Scott Davis, Susan Murray et al. · Cell Metabolism · 2006 · 2K citations · Full text

Mir-122 Regulation, Molecular Physiology, Lipid Synthesis +12

Hepatic and glucagon-like peptide-1–mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors

Kyle W. Sloop, Julia X.C. Cao, Angela M. Siesky et al. · Journal of Clinical Investigation · 2004 · 210 citations · Full text

Reduction of Hepatic and Adipose Tissue Glucocorticoid Receptor Expression With Antisense Oligonucleotides Improves Hyperglycemia and Hyperlipidemia in Diabetic Rodents Without Causing Systemic Glucocorticoid Antagonism

Lynnetta M. Watts, Vara Prasad Manchem, Thomas A. Leedom et al. · Diabetes · 2005 · 136 citations · Full text

Glucocorticoid, Insulin Signaling, Gastrointestinal Peptide Hormone +16

Cysteine Proteinase Inhibitors Decrease Articular Cartilage and Bone Destruction in Chronic Inflammatory Arthritis

Ronald E. Esser, Richard A. Angelo, Mark D. Murphey et al. · Arthritis & Rheumatism · 1994 · 122 citations

Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial

Rohit Loomba, Erin Morgan, Lynnetta M. Watts et al. · ˜The œLancet. Gastroenterology & hepatology · 2020 · 114 citations

Metabolic Syndrome, Placebo-controlled Phase 2, Hepatology +13